NOVO NORDISK A/S overview

...

Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) and reminds investors of the March 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of...

Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer PR Newswire PLAINSBORO, N.J., March 24, 2025 The Wegovy ® savings offer is good for all dose strengths of Wegovy ® Eligible cash-paying patients can redeem this offer at the retail pharmacy of their choice PLAINSBORO, N.J. , March 24, 2025 /PRNewswire/ -- Today, Novo Nordisk announced updates to the Wegovy ® savings program, allowing all eligible cash-paying patients access...

The Gross Law Firm Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline PR Newswire NEW YORK, March 24, 2025 NEW YORK , March 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to...

NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit PR Newswire NEW YORK, March 23, 2025 NEW YORK , March 23, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024 , both dates inclusive (the "Class Period"), of the important March 25, 2025 lead plaintiff deadline. So what: If you purchased Novo Nordisk securities during...

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024. Novo describes itself as a “healthcare company, focused on the research, development, manufacturing, and distribution of pharmaceutical productions globally.” For more information, submit a form , email attorney Phillip Kim, or give us a call at 866-767-3653. The...

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk PR Newswire NEW YORK, March 22, 2025 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo Nordisk To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Novo Nordisk between November 2, 2022 and December 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi...

Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO PR Newswire NEW YORK, March 21, 2025 NEW YORK , March 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between November 2,...